NewAmsterdam Pharma Statistics Share Statistics NewAmsterdam Pharma has 112.63M
shares outstanding. The number of shares has increased by 5.42%
in one year.
Shares Outstanding 112.63M Shares Change (YoY) 5.42% Shares Change (QoQ) 0.32% Owned by Institutions (%) 99.59% Shares Floating 54.88M Failed to Deliver (FTD) Shares 33 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 8.43M, so 7.49% of the outstanding
shares have been sold short.
Short Interest 8.43M Short % of Shares Out 7.49% Short % of Float 8.93% Short Ratio (days to cover) 6.71
Valuation Ratios The PE ratio is -10.04 and the forward
PE ratio is -17.15.
NewAmsterdam Pharma's PEG ratio is
-0.53.
PE Ratio -10.04 Forward PE -17.15 PS Ratio 53.22 Forward PS 113.4 PB Ratio 3.2 P/FCF Ratio -15.23 PEG Ratio -0.53
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for NewAmsterdam Pharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.08,
with a Debt / Equity ratio of 0.
Current Ratio 8.08 Quick Ratio 8.08 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $670.04K Profits Per Employee $-3.55M Employee Count 68 Asset Turnover 0.05 Inventory Turnover n/a
Taxes Income Tax -1K Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 68.33% in the
last 52 weeks. The beta is 0.03, so NewAmsterdam Pharma's
price volatility has been higher than the market average.
Beta 0.03 52-Week Price Change 68.33% 50-Day Moving Average 25.24 200-Day Moving Average 21.86 Relative Strength Index (RSI) 69.35 Average Volume (20 Days) 887,871
Income Statement In the last 12 months, NewAmsterdam Pharma had revenue of 45.56M
and earned -241.6M
in profits. Earnings per share was -2.56.
Revenue 45.56M Gross Profit 45.56M Operating Income -176.29M Net Income -241.6M EBITDA -241.49M EBIT -241.6M Earnings Per Share (EPS) -2.56
Full Income Statement Balance Sheet The company has 771.74M in cash and 448K in
debt, giving a net cash position of 771.29M.
Cash & Cash Equivalents 771.74M Total Debt 448K Net Cash 771.29M Retained Earnings n/a Total Assets 815.11M Working Capital 733.34M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -158.56M
and capital expenditures -672K, giving a free cash flow of -159.24M.
Operating Cash Flow -158.56M Capital Expenditures -672K Free Cash Flow -159.24M FCF Per Share -1.69
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -386.91% and -530.25%.
Gross Margin 100% Operating Margin -386.91% Pretax Margin -530.25% Profit Margin -530.25% EBITDA Margin -530% EBIT Margin -386.91% FCF Margin -349.49%
